eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
4/2018
vol. 22
 
Share:
Share:
more
 
 
abstract:
Review paper

Efficacy and safety of megestrol in the management of hepatocellular carcinoma: a systematic review of the literature

Prashanth Rawla, Krishna Chaitanya Thandra, Anantha Vellipuram, Citra Dewi Mohd Ali

Contemp Oncol (Pozn) 2018; 22 (4): 209-214
Online publish date: 2018/12/31
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death worldwide. There is as yet no standard therapy for inoperable HCC. We aimed to systematically review all health-related evidence regarding the effectiveness and safety of megestrol in HCC patients.

Material and methods
We conducted a systematic computerised search in PubMed, Scopus, Web of Science, Embase, and Cochrane CENTRAL. All original human studies reporting the efficacy of megestrol in HCC patients were included in our review.

Results
Six studies including 357 patients were finally eligible. The overall mean survival time of 87 megestrol-treated patients, was 9.187 (95% CI 1.134–17.239) months. Eight patients had tumour size enlargement, and eight patients had tumour size reduction. From three studies including 76 patients, 42 patients reported having improvement of appetite and food intake after receiving megestrol. Diverse adverse events were noticed between studies; however, they were tolerable in most of the studies.

Conclusions
To summarise, no conclusive evidence should be declared regarding the effectiveness of megestrol in patients with inoperable HCC. However, previous studies have shown promising results at the level of prolonging the survival rate, tumour size reduction, and improving the quality of life. Therefore, we recommend that future research studies must examine the role of megestrol in large-population, randomised studies.

keywords:

megestrol, Megace, hepatocellular carcinoma, HCC, progestin, oestrogen receptor, hormonal therapy

references:
Parkin DM. Global cancer statistics. CA Cancer J Clin 2005; 55: 74-108.
Hepatocellular carcinoma – United States, 2001-2006. MMWR Morb Mortal Wkly Rep 2010; 59: 517-520.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-34.
Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2014; 10: 153-161.
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-442.
Llovet JM, Ducreux M, Lencioni R, et al. European Association for the Study of the Liver European Organisation for Research and Treatment of Cancer: EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022.
Federico A, Orditura M, Cotticelli G, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma and Child-Pugh A or B cirrhosis. Oncol Lett 2015; 9: 1628-1632.
Giacomin AS, Sergio A, Vanin V, Tartaro P, Paccagnella D, Mazzucco M, Farinati F. Megestrol and embryonic extracts in the treatment of advanced hepatocellular carcinoma: A prospective randomized trial in the pre-sorafenib era. Hepatol Res 2010; 40: 153-160.
Nowak A, Findlay M, Culjak G, Stockler M. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev 2004; Cd001024.
Villa ED, Dugani A, Fantoni E, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996; 56: 3883-3885.
Liu C-L, Fan S-T, Ng O-L, et al. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study. Am J Gastroenterol 2000; 95: 218.
Zhang KC, Chow PK. The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo. Clin Cancer Res 2004; 10: 5226-5232.
Chao YC, Chan WK, Wang SS, et al. Phase II study of megestrol acetate in the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 1997; 12: 277-281.
Villa EF, Ferretti I, Grottola A, et al. Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors. Br J Cancer 2001; 84: 881-885.
Chow PK, Machin D, Chen Y, et al. Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer 2011; 105: 945-952.
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005; 5: 13.
Cappa FM, Cantarini MC, Magini G, et al. Effects of the combined treatment with thalidomide, megestrol and interleukin-2 in cirrhotic patients with advanced hepatocellular carcinoma. Dig Liver Dis 2005; 37: 254-259.
Colleoni M, Nelli P, Vicario G, Mastropasqua G, Manente P. Megestrol acetate in unresectable hepatocellular carcinoma. Tumori 1995; 81: 351-353.
Abou-Alfa GK. Hepatocellular carcinoma: molecular biology and therapy. Semin Oncol 2006; 33: S79-83.
Di Maio MD, Daniele B, Pignata S, et al. Is human hepatocellular carcinoma a hormone-responsive tumor? World J Gastroenterol 2008; 14: 1682-1689.
David A, Edwards K, Fellowes K, Plummer J. Anti-ovulatory and other biological properties of megestrol acetate 17acetoxy-6 methyl pregna 4: 6-diene-3: 20-dione (BDH 1298). J Reprod Fertil 1963; 5: 331-346.
Cooke BA, Vallance DK. Metabolism of megestrol acetate and related progesterone analogues by liver preparations in vitro. Biochem J 1965; 97: 672-677.
Pascual López A, Roqué i Figuls M, Urrútia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, Herdman M. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004; 27: 360-369.
Farinati FG, Gianni S, De Giorgio M, Fiorentini, S. Megestrol treatment in patients with hepatocellular carcinoma. Br J Cancer 2001; 85: 1606-1607.
Quek RS, Thye Lim S, Ong S. Hepatocellular carcinoma – Pathological complete response to oral capecitabine, megestrol and thalidomide. Acta Oncol 2006; 45: 95-97.
Friedman MA, Demanes DJ, Hoffman PG Jr. Hepatomas: Hormone receptors and therapy. Am J Med 1982; 73: 362-366.
Villa E, Dugani A, Fantoni E, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996; 56: 3883-3885.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe